What is HC Wainwright’s Forecast for RenovoRx Q3 Earnings?

RenovoRx, Inc. (NASDAQ:RNXT) – Stock analysts at HC Wainwright issued their Q3 2027 earnings per share (EPS) estimates for shares of RenovoRx in a note issued to investors on Friday, August 14th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($0.01) per share for the quarter. The consensus estimate for RenovoRx’s current full-year earnings is ($0.31) per share.

RenovoRx (NASDAQ:RNXT) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. RenovoRx had a negative return on equity of 138.07% and a negative net margin of 621.71%.The company had revenue of $0.91 million during the quarter, compared to the consensus estimate of $0.70 million.

A number of other research analysts have also recently weighed in on the stock. Wall Street Zen upgraded shares of RenovoRx from a “sell” rating to a “hold” rating in a research note on Saturday. Ascendiant Capital Markets increased their price target on RenovoRx from $13.50 to $14.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Finally, Weiss Ratings raised RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

RenovoRx Price Performance

Shares of NASDAQ:RNXT opened at $1.20 on Monday. The firm’s 50 day simple moving average is $0.96 and its two-hundred day simple moving average is $0.94. The company has a market capitalization of $54.06 million, a P/E ratio of -3.87 and a beta of 0.99. RenovoRx has a 1-year low of $0.70 and a 1-year high of $1.50.

Institutional Investors Weigh In On RenovoRx

Hedge funds have recently bought and sold shares of the business. XTX Topco Ltd lifted its position in RenovoRx by 58.6% during the fourth quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after purchasing an additional 18,525 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in shares of RenovoRx in the 2nd quarter worth $98,000. Citadel Advisors LLC bought a new stake in shares of RenovoRx in the 3rd quarter worth about $154,000. Wealthspire Advisors LLC bought a new stake in shares of RenovoRx in the 4th quarter worth about $212,000. Finally, Geode Capital Management LLC raised its position in shares of RenovoRx by 9.9% during the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after buying an additional 31,730 shares in the last quarter. Hedge funds and other institutional investors own 3.10% of the company’s stock.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.